Date: 2011-06-06
Type of information: Licensing agreement
Compound: meganuclease technology for the design and development of a new generation of living attenuated vaccines.
Company: Cellectis (France) Vitamfero (France)
Therapeutic area: Veterinary medicine
Type agreement: R&D
licensing
Action mechanism:
Disease:
Details: Cellectis, the genome engineering specialist, and VitamFero, a biotech company of the Genopole® portfolio developing new vaccines against parasite infections, have signed a research, development and licensing partnership agreement. This agreement will grant VitamFero access to Cellectis’ proprietary meganuclease technology for the design and development of a new generation of living attenuated vaccines. Under this 5-year agreement, Cellectis will supply VitamFero with preselected meganucleases for initial use in the development of vaccines against parasites responsible for toxoplasmosis, neosporosis, and others.
Financial terms:
Latest news:
